Materias dentro de su búsqueda.
Mostrando 34,581 - 34,600 Resultados de 34,656 Para Buscar 'biguru~', tiempo de consulta: 1.77s Limitar resultados
  1. 34581
    “…The data as a whole provides a strong rationale for a controlled clinical trial of PGLG toreducesevere COVID-19 in high-risk SCD patients and improve outcomes if infection occurs. [Figure: see text] DISCLOSURES: Cengiz:Biruni University Medical Faculty:Current Employment;Istanbul University-Cerrahpasa Medical Faculty:Ended employment in the past 24 months.Yavuzer:Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Geriatrics:Current Employment.Yavuzer:Biruni University Medical Faculty:Current Employment;Istanbul University-Cerrahpasa Mediacl Faculty:Ended employment in the past 24 months.Tang:Kaiser Permanente:Current Employment.Ward:Emmaus Medical, Inc.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Actions of L-Glutamine vs. COVID-19 Suggest Additional Benefit in Sickle Cell Disease
  2. 34582
    “…Ab response persists at 3 months; the study is ongoing and further data will be available at time of meeting. [Figure: see text] DISCLOSURES: Tucci:Amgen: Consultancy. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases
  3. 34583
    “…Pts with active HMs or those within 2 years of last therapy should be particularly aware of the risk of infection despite vaccines and should be considered for strategies to enhance anti-COVID-19 immunity regardless of age. [Figure: see text] DISCLOSURES: Olszewski:  TG Therapeutics: Research Funding; PrecisionBio: Research Funding; Celldex Therapeutics: Research Funding; Acrotech Pharma: Research Funding; Genentech, Inc.: Research Funding; Genmab: Research Funding.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
  4. 34584
    “…Acknowledgments: This study was funded by Cure Leukaemia under the Trials Acceleration Program (TAP), and grants from BMS and Blood Cancer UK. [Figure: see text] DISCLOSURES: Loke:  Novartis: Other: Travel; Janssen: Honoraria; Amgen: Honoraria; Pfizer: Honoraria; Daichi Sankyo: Other: Travel. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
  5. 34585
    “…Monitoring AB development in all allo-HCT recipients and vulnerable patients with other immunocompromising conditions may be crucial to determine those at increased risk for infection and for the timing of booster vaccines. [Figure: see text] DISCLOSURES: Manz:  CDR-Life Inc: Consultancy, Current holder of stock options in a privately-held company; University of Zurich: Patents & Royalties: CD117xCD3 TEA.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
  6. 34586
    “…Conclusion This study shows the interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allograft as more patients are documented with less decrease of IgG titers and the highest IgG values after V3. [Figure: see text] DISCLOSURES: Moreau:  Abbvie: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Sanofi: Honoraria; Celgene BMS: Honoraria; Oncopeptides: Honoraria.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
  7. 34587
    “…Thus, the access to SARS-COV2 mAb in this population who is at increased risk for complications from SARS-COV2 infection is critical in reducing progression to severe COVID-19 disease and hospitalization. [Figure: see text] DISCLOSURES: Ali:  Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Membership on an entity's Board of Directors or advisory committees; BMS: Speakers Bureau. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
  8. 34588
    “…Further prospective studies should ascertain the value of a 3 (rd) vaccine dose in this population. [Figure: see text] DISCLOSURES: Mahmoudjafari:  Omeros: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination
  9. 34589
    “…These data serve as pre-clinical validation for an ongoing clinical trial utilizing related HLA-matched and haplo-identical SARS CoV-2 vCTLs for the treatment of patients with mild and moderate SARS-CoV-2 disease (IND #27260, NCT# 04896606). [Figure: see text] DISCLOSURES: Lee:  Kiadis Pharma: Divested equity in a private or publicly-traded company in the past 24 months, Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Courier Therapeutics: Current holder of individual stocks in a privately-held company. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System
  10. 34590
    “…By contrast, Kenya and Indonesia have <30, Laos and Morocco <20, Tanzania and Bolivia <10, and Mauritania only 1 km per 100 km(2). As these figures show, there is a significant backlog of transport infrastructure investment in both rural and urban areas, especially in sub‐Saharan Africa. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Studies of the effectiveness of transport sector interventions in low‐ and middle‐income countries: An evidence and gap map
  11. 34591
    por Bader, Mohamed, Al-Hassani, Hayder
    Publicado 2021
    “…Findings were then grouped into generic categories such as infectious, cardiac, etc. (see Figure 7). ECG: All patient notes were examined in the ‘Investigations’ section to determine if an ECG was included. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Physical health audit of gwent specialist substance misuse services (North Team)
  12. 34592
    por catherine, Auxilia, Anushya, Neelakandan
    Publicado 2022
    “…. — Further neuropsychological testing identified a global reduction in general intellectual function, with severe executive function deficits as well as poor verbal working — Neurology opinion obtained as a case of young onset FTD — MRI scan of the brain showed substantial bilateral, symmetrical frontal atrophy, with no evidence of white matter changes that would be typical of a vascular, vasculitic or inflammatory cause (figure 1). In addition, autoimmune encephalitis was negative; and HIV and syphilis serology were all normal or negative. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Case Report On Young Onset Frontal Temporal Dementia Presented As Catatonia
  13. 34593
    “…There was no difference between sadness group and neutral emotion group (P = 0.504) (see Figure 2b). The main effect of emotion on MCT injury was significant, f (2, 99) = 4.01, P = 0.021, η 2p=0.08. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    THE IMPACT OF CHINESE ENTREPRENEURS' EMOTIONAL LABOR AND WORK PRESSURE ON EXPORT PROFITABILITY: EVIDENCE FROM CHINA
  14. 34594
    “…Preliminary employee satisfaction surveys also reveal a high degree of satisfaction when working from home. [Figure: see text] DISCLOSURES: Gerds:Apexx Oncology: Consultancy; Imago Biosciences: Research Funding; AstraZeneca/MedImmune: Consultancy; Roche/Genentech: Research Funding; Gilead Sciences: Research Funding; Incyte Corporation: Consultancy, Research Funding; Sierra Oncology: Research Funding; Celgene: Consultancy, Research Funding; Pfizer: Research Funding; CTI Biopharma: Consultancy, Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic
  15. 34595
    “…The entire list of differentially expressed genes was found to be significantly associated with 42 canonical pathways, including 25 up-regulated and 17 down-regulated pathways in early FAI group (Figure-2). Several pathways: Peroxisome proliferator-activated receptor (PPAR) signaling pathway, Phosphatidylinositol-3-kinase/activate protein kinase (PI3K/Akt) signaling pathway, and Hypoxia-inducible factor 1 (HIF1) have been previously reported as associated with OA. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Poster 197: Understanding the Biological Pathway of Progression of Hip OA Disease through Transcriptome Analysis
  16. 34596
    “…The pooled placebo clinical response rate was 24.4% [95% CI 12.4%, 38.4%] (Figure 1), with substantial heterogeneity (I2=60.8%, p<0.01). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A180 PLACEBO RATES IN MICROSCOPIC COLITIS RANDOMIZED TRIALS: APPLICATIONS FOR FUTURE DRUG DEVELOPMENT USING A HISTORICAL CONTROL ARM
  17. 34597
    “…[Figure: see text] CONCLUSION: These data support the selection of sulopenem etzadroxil/probenecid 500 mg/500 mg PO q12h, which minimized the potential for on-therapy drug-resistance amplification. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
  18. 34598
    “…With approximately 32 months of median follow up, neither median leukemia-free survival (mLFS) nor mOS had been reached (Figure 1). Twelve pts (17%) went on to allogeneic stem cell transplant. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
  19. 34599
    por Liisborg, Charlotte
    Publicado 2022
    “…Vi foreslår derfor en AMD‐model (Figur 18) hvor inflammation kan initiere og accelerere den normale aldersafhængige akkumulation af affaldsstoffer i nethinden, som senere udvikler sig til druser, medførende øget lokal inflammation og med tiden tidlig og intermediær AMD. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Age‐related macular degeneration and myeloproliferative neoplasms – A common pathway
  20. 34600
    “…As at 6 hours L(+) was only 72 and at 28 hours only 91, we doubt whether L(+) ever reaches above 150, and therefore hardly expect Ehrlich's figures of 200 to be realized. When we seek to analyze the above-described process, we find certain facts which seem partly to explain it. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    THE RELATION OF THE TOXICITY OF DIPHTHERIA TOXIN TO ITS NEUTRALIZING VALUE UPON ANTITOXIN AT DIFFERENT STAGES IN THE GROWTH OF CULTURE
Herramientas de búsqueda: RSS